- Northera Effectively Increases SBP in Patients With Neurogenic Orthostatic Hypotension
- Patients Showed Mean Diurnal Increase of 8.4 mmHg SBP and Mean Nocturnal Increase of 7.8 mmHg SBP While on Northera
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported findings from Study 305, a study evaluating the effect of Northera™ (Droxidopa), an investigational agent being studied for the treatment of neurogenic orthostatic hypotension (NOH), on patients' 24-hour blood pressure (BP) profile.
Study 305 evaluated the blood pressure effects of Northera by comparing two 24-hour continuous BP monitoring periods in 18 patients with symptomatic NOH enrolled in Chelsea's ongoing Phase III Study 301. Blood pressure readings were initially recorded for 24 consecutive hours while patients were off drug during the washout phase of Study 301. These were then compared to similar readings recorded following Study 301 while patients were on active drug treatment during open-label extension studies.